Next-Generation Cannabinoid Therapeutics

Kalytera is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics.

About KalyteraGvHD Program

About Kalytera

Kalytera Therapeutics (TSXV: KALY) is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”). Kalytera is also developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition. Learn more >>

Recent Press Releases

GvHD Program

Kalytera is developing a clinical-stage cannabidiol (“CBD”) medicine to prevent and treat Graft versus Host Disease (“GvHD”). GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. Learn more about GvHD >>

Program Highlights
  • Four Phase 2a clinical trials complete, one published study demonstrating proof-of-concept
  • Orphan Drug Designation (“ODD”) granted in U.S. and Europe
  • Urgent unmet need; there are currently no FDA approved therapies for the prevention or treatment of GvHD in its acute and chronic forms

About CBD

CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life.

Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition. Learn more about CBD >>